330793-09-4

Basic information

• Product Name: TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE
• Synonyms: 3-(BOC-AMINO)PHENYLBORONIC ACID PINACOL ESTER;3-(TERT-BUTOXYCARBONYLAMINO)PHENYLBORONIC ACID, PINACOL ESTER;T-BUTYL N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE-2-YL)PHENYL]CARBAMATE;TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE;3-(N-Boc-amino)phenylboronic acid pinacol ester, 97%;Carbamic acid, [3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, 1,1-dimethylethyl ester (9CI);tert-Butyl-N-[3-(4,4,5,5-tetramethyl-1,3,2-;3-(Boc-amino)benzeneboronic acid pinacol ester, 97%
• CAS NO: 330793-09-4
• Molecular Formula: C₁₇H₂₆BNO₄
• Molecular Weight: 319.2
• EINECS: 200-528-9
• Product Categories: N-BOC;6
• Mol File: 330793-09-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 148-153 °C(lit.)
• Boiling Point: 387 °C at 760 mmHg
• Flash Point: 187.8 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 3.4E-06mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.97±0.70(Predicted)
• CAS DataBase Reference: TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE(330793-09-4)
• EPA Substance Registry System: TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE(330793-09-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 330793-09-4(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE is a chemical compound that belongs to the class of carbamates. It is a tert-butyl derivative and contains a boron atom in its chemical structure. TERT-BUTYL-N-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]CARBAMATE is commonly used as a reagent in organic synthesis and as a building block for the preparation of various pharmaceuticals and agrochemicals. Its unique structure and functional groups make it valuable for the development of new materials and compounds with potential biological activity. However, it is important to handle and use this compound with proper safety precautions as it may pose risks to human health and the environment.

InChI:InChI=1/C17H26BNO4/c1-15(2,3)21-14(20)19-13-10-8-9-12(11-13)18-22-16(4,5)17(6,7)23-18/h8-11H,1-7H3,(H,19,20)

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 25216-74-4 tert-butyl (3-bromophenyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 210907-84-9 3-aminophenylboronic acid pinacolate 
• 591-19-5 m-Bromoaniline 

Downstream Products

• 873566-71-3 4-[3-(N-tert-butoxycarbonylamino)phenyl]-2-(3-hydroxymethylphenyl)-6-morpholinopyrimidine 
• 1352615-43-0 C₅₆H₆₀N₂ 
• 1352615-65-6 C₆₈H₆₆Br₂N₂ 
• 817618-57-8 tert-butyl methyl-[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]carbamate 
• 887831-90-5 (3-((tert-butoxycarbonyl)(methyl)amino)phenyl)boronic acid 

Relevant articles and documents

ANTI-CD40 ANTIBODY DRUG CONJUGATES

Provided herein are anti-CD40 antibody drug conjugates comprising a radical of Formula (I), wherein R1, R2, and R3 are as defined herein. Further provided are anti-CD40 antibody drug conjugates of Formula (II), wherein Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2, and R3 are as defined herein. Further provided are pharmaceutical compositions and kits thereof, and methods of using same.

GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

CaMKII INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of Ca2+/calmodulindependent protein kinase (CaMKII), compositions thereof, and methods of using the same. Cardiovascular disease remains the number one cause of death in developed countries. Furthermore, incidence of cardiovascular disease has increased dramatically in developing countries. Although cardiovascular disease usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life, making primary prevention efforts necessary from childhood.